Nyxoah SA is a medical technology company specializing in the development and commercialization of innovative solutions for treating obstructive sleep apnea (OSA). Its flagship product, the Genio system, offers a CE-marked, patient-centric, minimally invasive hypoglossal neurostimulation therapy designed for moderate to severe OSA cases. This battery-free implant stimulates the hypoglossal nerve to maintain airway patency during sleep, providing an alternative to traditional CPAP machines. Incorporated in 2009 and headquartered in Mont-Saint-Guibert, Belgium, Nyxoah SA focuses on expanding its global footprint, highlighted by recent FDA approval enabling U.S. market entry and commercial launches in Europe, including the Netherlands. The company supports its growth through manufacturing expansions in Belgium, surgeon training programs, and financing initiatives to bolster commercialization, clinical studies, and R&D. With approximately 184 employees, Nyxoah SA plays a pivotal role in the medtech sector by addressing unmet needs in sleep disorder treatments, fostering advancements in neuromodulation therapies amid rising OSA prevalence worldwide.